Skip to main content
logo
Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
60.56
-0.21 (-0.35%)
Aug 24, 2026, 4:00 PM EDT - Market closed

Xenon Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-7.5--9.4318.44
Revenue Growth
-----48.83%-42.68%
Gross Profit
-352.49-293.44-210.39-167.51-96.33-57.03
Operating Income
-441.59-373.07-279.3-214.05-129.14-78.99
Net Income
-409.2-345.91-234.33-182.39-125.37-77.09
Earnings Per Share
-4.73-4.36-3.01-2.73-2.07-1.77
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,245586.04754.4930.87720.77551.77
Total Debt
6.427.949.0210.910.448.26
Net Cash (Debt)
1,239578.09745.39919.97710.33543.52
Net Cash Growth
101.04%-22.44%-18.98%29.51%30.69%212.94%
Net Cash Per Share
14.317.299.5713.7511.7312.46

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-337.52-279.12-181.39-151.11-101.03-69.5
Capital Expenditures
-1.01-0.8-3.08-5.62-2.89-2.05
Free Cash Flow
-338.53-279.92-184.46-156.73-103.92-71.55
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
--4974.27%---1368.91%-428.45%
Pretax Margin
--4598.59%---1327.70%-427.88%
Profit Margin
--4612.13%---1328.95%-418.11%
FCF Margin
--3732.23%---1101.57%-388.09%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-21.6521.6521.6521.6521.65
PS Ratio
-461.80--261.4189.14